Skip to main content

Deracemization of Beta2- and Gamma2-amino acids

NIGMS - National Institute of General Medical Sciences

open
OpenLast verified: 2026-06-20

About This Grant

PROJECT SUMMARY/ABSTRACT The pharmaceutical and agrochemical industries rely heavily on the stereoselective preparation of chiral molecules because opposite enantiomers often demonstrate disparate activities. Though numerous approaches exist to obtain enantiomerically enriched material, these methods typically require the synthesis of specialized starting materials/reagents. The catalytic deracemization of racemic material is an attractive alternative, as racemic synthesis is often straightforward and enantioinduction can be achieved by a catalytic rather than stoichiometric process. In recent years, photocatalysis has emerged as a strategy for driving systems out of equilibrium and accomplishing deracemization reactions. However, despite the prevalence of the α-carbonyl stereocenter in peptidomimetics, natural products, and pharmaceuticals, the catalytic deracemization of this scaffold has not been achieved in a general sense; this may be in part due to the challenges associated with generating a reactive intermediate at the acidic α-position under mild conditions, coupled with the lack of nucleophilic HAA reagents. This proposal seeks to unlock a new reactivity platform within the field of stereochemical editing and utilize it to enable deracemization of α-carbonyl stereocenters. Leveraging the Wendlandt group’s expertise in asymmetric catalysis, we will investigate stereoselective hydrogen atom abstraction (HAA) using chiral amine-borane catalysts and develop a deracemization protocol for the conversion of racemic starting materials into high-value enantioenriched products. Prior literature has established proof of concept for kinetic resolution of α-carbonyl stereocenters with these reagents, albeit with modest selectivity outcomes; however, their extension to deracemization has not yet been investigated or accomplished. We seek to leverage these chiral amine-boryl radicals and photoredox catalysis for the development of a novel method for the deracemization of α-carbonyl stereocenters, with a particular focus on biologically active motifs such as β2- and γ2- amino acids. Ultimately, we seek to establish amine-boranes as a modern reagent class for selective HAA of acidic C–H bonds and gain a deeper understanding of the factors affecting enantioselectivity of HAA with amine-boryl radical species. We will accomplish these goals through synthesis of novel catalysts and evaluation of their reactivity via spectroscopic studies. Research will be carried out at MIT, an institution that excels in synthetic chemistry. I will receive training in asymmetric catalysis from Prof. Alison Wendlandt, a trailblazer in the stereochemical editing field, training in photophysics from Prof. Schlau-Cohen, an expert in ultrafast spectroscopy, as well as training in organoboron chemistry through informal interactions with Prof. Robert Gilliard and his research group at MIT. The proposed research is highly complementary to my doctoral training in the data science-driven study of pharmaceutically relevant reactions, enabling me to expand my skillset to include asymmetric catalysis, photophysics, and main group catalysis.

Grant Summary

Deracemization of Beta2- and Gamma2-amino acids is a NIGMS - National Institute of General Medical Sciences grant providing up to $75K for university, nonprofit, healthcare org. Applications are due 2027-11-15 (open). Check eligibility and apply with FindGrants.

Not quite the right fit?

Search 9,000+ open grants, or get matches ranked for your organization — free.

Focus Areas

health research

Eligibility

universitynonprofithealthcare org

How to Apply

Funding Range

Up to $75K

Deadline

2027-11-15

Complexity
Medium
  1. 1Confirm your organization is eligible for Deracemization of Beta2- and Gamma2-amino acids from NIGMS - National Institute of General Medical Sciences, checking organization type, location, and any population or project requirements.
  2. 2Gather the required documents and information, including your organization details, project plan, and budget figures.
  3. 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
  4. 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIGMS - National Institute of General Medical Sciences before the deadline.
This record is a past award, contract, or funder profile — useful for research, but not an open grant application. Check the original source for current opportunities from this funder.

Don't want to draft it yourself?

We'll draft the complete application against NIGMS - National Institute of General Medical Sciences's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.

AI Requirement Analysis

Detailed requirements not yet analyzed

Have the NOFO? Paste it below for AI-powered requirement analysis.

0 characters (min 50)

Deracemization of Beta2- and Gamma2-amino acids: Frequently Asked Questions

Who is eligible for the Deracemization of Beta2- and Gamma2-amino acids?

Deracemization of Beta2- and Gamma2-amino acids is offered by NIGMS - National Institute of General Medical Sciences and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.

How much funding does the Deracemization of Beta2- and Gamma2-amino acids provide?

Deracemization of Beta2- and Gamma2-amino acids provides up to $75K per award from NIGMS - National Institute of General Medical Sciences. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.

When is the Deracemization of Beta2- and Gamma2-amino acids deadline?

Applications for Deracemization of Beta2- and Gamma2-amino acids are due 2027-11-15 (open). Because deadlines can change, verify the date with the funder, NIGMS - National Institute of General Medical Sciences, and give yourself enough time to prepare a complete, competitive application before the close date.

How do you apply for the Deracemization of Beta2- and Gamma2-amino acids?

To apply for Deracemization of Beta2- and Gamma2-amino acids, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIGMS - National Institute of General Medical Sciences.